Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million

Reuters

2025/11/07

<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million

Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581009971"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581009971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581009971?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581009971","market":"fut","top_or_hot":-1,"title":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> reports Q3 revenue of $30.6 million and net income of $5.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7qhZlX:1","article_id":"2581009971","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581009971","pubTimestamp":1762513222,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","GYRE":"Gyre Therapeutics","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Gyre Therapeutics报告第三季度营收为3060万美元，净利润为590万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":0.9,"NDAQ":0.9},"content_text":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million\n    \n\n        Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571120-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}